To develop a system for overexpressing genes in the vascular wall, we created transgenic mice using the reporter gene luciferase and the murine preproendothelin-1 promoter. In vitro analysis suggested that the murine 5'-flanking region contained endothelial-specific elements in a 5.9-kb fragment. Five Clin. Invest. 1995. 95:1335-1344 
Introduction
Atherosclerosis results in the cardiovascular complications of myocardial infarction, stroke, and peripheral vascular disease and is a leading cause of mortality and morbidity. A recent review of the pathophysiology of atherosclerosis lists over 35 potential mediators of this complex disease (1) . Because many of these molecules have been identified by in vitro analysis, much current research is directed towards analyzing the significance of each of these potential molecular targets in vivo. One powerful new approach that could be useful in such analyses is the creation of transgenic mice which overexpress or inhibit select proteins implicated in the atherogenic process. A limitation in the field has been the lack of a system to target gene expression specifically to the vessel wall. Endothelin-1 is a 21-amino acid peptide which was originally characterized as a potent vasoconstrictor synthesized by endothelial cells (2) . The expression of endothelin-1 in mammals is fairly specific for the endothelium, although there is some expression in other cells, mainly the airway and gastrointestinal epithelium, neurons, and glomerular mesangial cells (3) (4) (5) (6) (7) (8) (9) (10) . Endothelin-1 is derived from the prepropeptide preproendothelin-l which has a promoter region with endothelial cell specificity as assessed by in vitro analysis (1 1-14) . Hence the 5'-flanking region of preproendothelin-] would appear attractive for in vivo gene targeting.
To avoid any species barrier to high levels of expression, we cloned and utilized the murine promoter region. After determining that larger flanking regions yielded greater expression in vitro, we used firefly luciferase as a reporter gene and determined the in vivo expression of immunoreactive protein and enzymatic activity directed by the 5.9-kb 5'-flanking region. To assure that this approach would yield reasonable levels of expression of a target protein, we also created transgenic mice overexpressing 15-lipoxygenase which has been implicated in the oxidation of low density lipoprotein in atherogenesis (15) .
Methods
Cloning ofthe murine preproendothelin gene. To obtain genomic clones for the murine preproendothelin-l (PPET-JI)' promoter region, oligonucleotide probes corresponding to the nucleotide sequence of the entire murine endothelin-1 (ET-1) coding sequence (16) were used to screen a BALB/c mouse genomic library (Clontech Laboratories Inc. Palo Alto, CA) under high stringency conditions. DNA sequencing was performed using the dideoxy chain termination method. A fragment containing the 5'-flanking region, of the PPET-J gene was subcloned, and the transcription start-site was determined by primer extension. All molecular biological procedures were standard (17, 18) .
Preproendothelin-Luciferase plasmids. To construct plasmids with the firefly luciferase as a reporter gene directed by the murine preproendothelin promoter, an EcoRI digest of the murine PPET-J genomic fragment, which includes 2.4-kb of the 5'-flanking region, the first exon of the gene and 0.8 kb of the first intron (Figs. 1 and 2), was subcloned into pBluescript (Stratagene, La Jolla, CA). From this subclone we excised a BamHI fragment which includes 1.4 kb of the 5'-flanking region, the first exon of the gene and 0.8 kb of the first intron and subcloned it into a second Bluescript plasmid (pl.4PPET-Blu). A BamHI digest of the pGL-basic vector (Promega, Madison, WI) containing the luciferase gene with its own ATG and stop codon as well as the SV40 intron/polyA signal, was cloned into the BglII site in the noncoding region of the first exon in the 1.4PPET-Blu plasmid (Fig. 2) . This resulted in the plasmid we used for in vitro studies and was called pl.4mPPET-LUC. We then cut out a BamHI-BamHI fragment from pl.4mPPET-LUC. This fragment contained the 1.4 kb of the 5'-flanking region, the first exon of the gene with the luciferase gene cloned into its BglII site and the 0.8 kb of the first intron. By inserting it downstream of a 4.5 kb HindIII-BamHI fragment from -5.9 to -1.4 kb of the murine PPET-J 5'-flanking region we created a vector which contained 5.9 kb of the 5'-flanking region (p5.9mPPET-LUC) (Fig. 2) . The other reporter plasmid containing 0.45 kb 5'-flanking region was also constructed in a similar fashion (pO.45mPPET-LUC) (Fig. 2) . For creating the plasmids with the 15-lipoxygenase directed by the preproendothelin promoter (pPPET-1SLO), the cDNA for the human enzyme was used (19) .
Cell culture and DNA transfection. Human umbilical vein endothelial cells (HUVEC) were generously provided by M. Mulkins. HUVEC and the bovine pulmonary artery endothelial cell line, CPAE (American Type Culture Collection, Rockville, MD) were grown on human fibronectin-coated flasks (Biomedical Technologies Inc., Stoughton, MA) in DME supplemented with 20% fetal calf serum, 150 Mg/ml endothelial cell growth supplement (Collaborative Research Inc., Bedford, MA), 0.1 U heparin/ml, 25 mM Hepes (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid), 1 mM sodium pyruvate, 1 mM non-essential amino acids solution, 50 U penicillin/ml, 50 Mg streptomycin/ml, and 2 mM glutamine. The murine fibroblast cell line, NIH 3T3, and the monkey kidney cell line, Cos-7, were grown in DEM supplemented with 10% fetal calf serum, 10 mM Hepes, 50 U penicillin/ml, 50 Mg streptomycin/ ml, and 2 mM glutamine. All cells were plated in 60-mm dishes at least 24 h before transfection. DNA transfection of HUVEC, CPAE, NIH 3T3, and Cos-7 cells were performed with lipofectin reagent (GIBCO BRL, Gaithersburg, MD) using standard technique (20) . The cells (-60% confluent) were transfected with 6 Mg of either the PPET-I luciferase fusion gene plasmids (with 5.9, 1.4, or 0.45 kb 5'-flanking promoter region) or with the SV40 minimal promoter-luciferase plasmid (pGL2-control vector; Promega). The vector pSV,fgalactosidase (4 Ag) (Promega) was used as an internal standard for the transfection efficiency. A plasmid with the 5.9-kb 5'-flanking region of the PPET-1 promoter and the luciferase gene in the reverse orientation was used as negative control. The cells were harvested 60 h after transfection and were assayed for luciferase and fi-galactosidase activity. bor, ME). Microinjected eggs were then transferred into the oviducts of CD-I foster mothers (Charles River Breeding Laboratories, Wilmington, MA) (18) . Founder mice were identified by luciferase activity assay of the tails and confirmed by Southern blot analysis of tail DNA using a 360-bp luciferase gene sequence as probe. Founders with high luciferase activity levels were crossbred for several generations with wild type C57B6/SJL mice to establish heterozygous colonies. PPET-1SLO Cl) Figure 4 . Tissue luciferase activity in two transgenic colonies derived from independent founders. 3-mo-old mice were sacrificed and the tissue expression of luciferase was measured as described in Methods. The mean and standard deviation of luciferase activity (light units per microgram of protein) are shown for mice from the lowest activity colony, tg5.9mPPETLUC-l (n = 13), and from the highest activity colony, tg5.9mPPETLUC-2 (n = 5).
immersed sequentially in PBS containing 0.5% BSA and 10% normal goat sera (blocking solution) (10 min), followed by blocking solution containing 10 jig/ml avidin (10 min), blocking solution containing 10 t.g/ml biotin (10 min), and primary rabbit anti-luciferase antisera 1:500/ 
Results
The genomic DNA sequence of the murine preproendothelin-I (PPET-J) promoter region has not been previously determined. A clone containing the endothelin-1 coding region (exon C! cI 2) and more than 10 kb of the 5'-flanking promoter region was obtained. The genomic clone was verified by sequencing exon 2 which encodes the mature ET-1 peptide. This exon sequence was identical to the known murine cDNA sequence (16) . Sequencing of 1,057 bp of 5'-flanking region, the first exon and 200 bp of the first intron of the murine gene ( Fig. 1) revealed 67% identity to the human preproendothelin promoter (12) (13) (14) . However, in some regions less than 20% identity was noted such as in the 66-bp region, +86 to +151, and in the 76 bp region, -695 to -770. The transcription start site, the CAAT and TATA consensus sequences, the first exon/intron junction, the GATA-2 and the AP-1 binding site and the NF-i binding element were identical both in sequence and in location in the murine and the human PPET-J gene (Fig. 1) . On the other hand, two other TPA-responsive elements are missing in the murine gene.
To evaluate which region of the murine preproendothelin-1 5'-flanking region would be useful for targeting gene expression to the vascular wall, we first constructed three plasmids with luciferase as a reporter gene directed by different 5'-flanking regions of the murine preproendothelin gene (Fig. 2) . The efficiency of each plasmid was tested by transfecting endothelial and non-endothelial cell lines and assessing luciferase activity. The plasmid containing the 5.9-kb region gave 5 and 7 times more luciferase activity in transfected bovine pulmonary artery endothelial cell line (CPAE) than the plasmids containing the 1.4 or the 0.45 kb regions respectively (Fig. 3) . In human endothelial cells (HUVEC) p5.9mPPET-LUC gave 2-3 times more luciferase activity than the plasmids containing the 1.4-or 0.45-kb regions (data not shown). To assess endothelial cell specificity, endothelial and non-endothelial cell lines were transfected with either the PPET-LUC plasmids or the SV40 minimal promoter-luciferase plasmid (pGL2-control vector; Promega). All three PPET-J constructs showed higher levels of expression in transfected endothelial than non-endothelial cell lines, with the most endothelial cell-specific construct being the p5.9mPPET-LUC (Fig. 3) . On the other hand non-endothelial cell lines yielded nine times more luciferase activity than did endothelial cells when transfected with constructs lacking the preproendothelin promoter (pGL2 vector). These sion was in the aorta. Although the different colonies showed different levels of luciferase expression, the tissue distribution was identical as shown for the lowest and the highest expressing colonies in Fig. 4 . The cellular distribution of expression in the aorta was studied next. Mouse aortic endothelial cells were selected by lectin magnetic beads, and cultured from 5 transgenic, and 5 nontransgenic mice. The "endothelial" fraction had 90% endothelial cells, and the "non-endothelial" fraction had < 10% endothelial cells, as determined by endothelial specific staining with anti-Von Willebrand antibody (data not shown). The luciferase activity was 4.3 times higher in the "endothelial" than in the "non-endothelial" cell fraction (41,750 and 9,673 light units/ 2 x 105 cells, respectively).
Immunohistochemical staining of the aorta (Fig. 5) showed high levels of luciferase expression in the aortic wall (Fig. 5 A) but not in the surrounding tissue as shown by nuclear staining with propidium iodide (Fig 5 B) . Endothelial-specific staining with anti-Von Willebrand antibody, and smooth muscle cellspecific staining with anti-actin antibody (data not shown) indicated that the luciferase expression was in the intima (endothelial cells), the media (smooth muscle cells), as well as the vasa vasorum. Staining of the aorta from 5.9PPET-LUC transgenic mice with preimmune serum and the aorta of a PPET-1SLO transgenic control mice with anti-luciferase antisera (Fig. 5 C) were both negative. High levels of expression were also noted in other large arteries, in small muscular arteries, and to a lesser extent in capillaries throughout the body (Figs. 6-7) . Lower levels of expression were noted in veins. Some organs such as the heart, kidney, and lung showed more vascular expression than others. The liver and the spleen showed minimal vascular expression. Even in the same organ some arteries showed high levels of expression while others showed little or none (Figs. 6  and 7) . In large, muscular arteries the expression was in the intima and media (Fig. 5 A, and Fig. 7 A) , but in small arteries, veins and capillaries the expression was confined to the endothelial cells.
In most organs the expression was confined to the vascular tissue, however, some nonvascular expression was detected as shown for the lung and the kidney (Figs. 6 and 7) . The most significant nonvascular expression was detected in the airway epithelium as indicated by luciferase activity in the trachea (Fig. 4) and by anti-luciferase staining of the lung (Fig. 6) . Similar expression was detected in salivary gland epithelium. The glomeruli showed high levels of expression both in the endothelial and the mesangial cells (Fig. 7 A) . The epithelium of the small intestine showed expression that increased gradually from the basal cells (no expression) toward the mature cells lining the lumen. Different regions of the brain showed different levels of luciferase expression (data not shown). This pattern was identical to the published distribution of endothelin expression in the brain (10) . Other select nonvascular cells showed much lower levels of luciferase activity. The pattern of immunofluorescence staining of frozen sections was confirmed by peroxidase staining of paraffin sections.
To further demonstrate the targeting capability of this system, we then used the 5'-flanking sequence of the murine preproendothelin-1 gene to express the human 15-lipoxygenase in transgenic mice as described in Methods. We have established two heterozygous colonies from independent founders. Mice from each colony have been analyzed for the expression of the heterologous 15-lipoxygenase enzyme by immunocytochemistry using an anti-human 15-lipoxygenase antibody. All mice analyzed have shown 15-lipoxygenase expression in the vascular wall of various organs as illustrated for the coronary and pulmonary arteries in Figs. 8 and 9 respectively. In nonvascular tissue, the highest expression was again observed in the airway epithelium (Fig. 9 ). Other nonvascular tissues showed minimal or no expression. The pattern of the vascular and non-vascular expression was similar to the luciferase expression as described above. Nontransgenic mice stained with 15-lipoxygenase antibody showed no immunoreactivity ( Fig. 8 and 9 ). In addition, transgenic mice stained with non-immune rabbit IgG as a further control showed no immunoreactivity (data not shown).
To confirm that the human 1 5-lipoxygenase expressed in the transgenic mice is enzymatically active we performed activity assays on various tissues and measured the enzyme product 15-HETE, as shown in Table II . In extracts of heart tissue from transgenic mice, 4.43±0.99 ng 15-HETE was detected per mg tissue (n = 8). This was significantly different (P < 0.01) from levels obtained from extracts of heart tissue of non-transgenic mice (0.026+0.03, n = 5). In aortic tissues of transgenic mice 5.86+0.49 ng 15-HETE per mg tissue was detected. Aortas of non-transgenic mice contained no detectable 15-HETE production. 15-HETE was also detected in tracheas and brains of transgenic mice (3.56+1.18 and 0.27±+0.06 ng/mg tissue respectively, n = 5) but not in non-transgenic mice (0.11±10.005 and 0.005±0.002 ng/mg tissue respectively, n = 3). Both differences were statistically significant (p < 0.05 and p < 0.01 respectively). No 15-HETE was detected in the livers of transgenic or nontransgenic mice. It is of interest that in the trachea the levels of 15-HETE (which is the product of the human 15-lipoxygenase) were up to 7 times higher than that of 12-HETE which is the product of the murine 12-lipoxygenase normally expressed in this organ. 
Discussion
Our data show that the murine preproendothelin promoter sequence can be used to direct significant in vivo gene expression to the vascular wall in transgenic mice. Expression in select epithelial cells, particularly those of the airway also occurs. However, expression in most non-vascular tissues is minor or non-existent. To avoid potential species differences in expression, we cloned the murine PPET-1 gene 5'-flanking region. Sequencing of 1 kb of the S'-flanking region yielded 67% identity with the published human sequence. The observation that in vitro transfection efficiency did not vary between constructs using 0.45 kb versus 1.4 kb of S'-flanking region is similar to that reported for the human promoter analysis (11) (12) (13) (14) . However, our results suggests that the -1.4 to -5.9 kb region may contain endothelial cell-specific elements, although further work is needed to confirm this. In any event, this study clearly suggests that larger fragments of the murine promoter are preferred when attempting tissue specific expression. This has not been the experience with the human gene (11) (12) . Five colonies of the tg5.9mPPET-LUC mice have been established and all five showed the same distribution of luciferase activity and immunostaining, suggesting that expression is unlikely to be very dependent on integration site. The most significant expression of luciferase was in the aorta and the vasculature throughout the body, but some organs showed more vascular expression than others. Even in the same organ some arteries showed high expression while others showed little or no expression. In addition, expression was often in the intima and media of large muscular arteries but only in endothelial cells in other vessels. Such uneven expression of endothelin within the vasculature of the same organ and from organ to organ has been previously described (4) (5) (6) (7) (8) (9) (10) 26) . In nonvascular cells the most significant expression was in the respiratory epithelium which is not surprising since these cells are known to express endothelin-1, although at a lower level than endothelial cells (5) . Hence, the pattern of vascular and non-vascular expression of luciferase in the transgenic mice is generally consistent with the previously described distribution of endothelin in mammals (4-10, 26). Minor differences in tissue distribution from this study and other reports would not be surprising since endothelin is a secretory protein with an unstable mRNA. Moreover, endothelin has a high sequence identity with other members of the endothelin family that includes endothelin-2 and endothelin-3 (27) (28) (29) (30) (31) . On the other hand, luciferase is a nonsecretory protein that has a stable mRNA and does not cross react in immunostaining with other murine proteins. Therefore the described system may offer distinct advantages in studying mechanisms of the regulation of endothelin-1 expression over analysis of endogenous gene products. Clearly, the transgenic mice described here will be valuable in studying the PPET-1 promoter in vivo.
Upon completion of this study we learned of an attempt to use the human preproendothelin-1 S'-flanking region to direct ,3-galactosidase expression to the vascular wall in transgenic mice (32) . The authors concluded that the levels of expression were too low to be of significant use as a gene targeting system.
No [3-galactosidase activity was reported, although immunostaining was observed. While endothelin-1 mRNA is easily detected by Northern analysis, the P-galactosidase transcripts in these mice could only be detected by reverse transcriptasepolymerase chain reaction (RT-PCR) and RNase protection. Moreover, some transgenic colonies did not show the same tissue distribution as expected with endothelin-1 and all of them had an unexplained expression in heart muscle cells. The authors suggest that some important regulatory elements are missing in their construct. In contrast, we have shown high, consistent levels of luciferase expression in the same distribution as expected for endothelin-1. Although luciferase is a more sensitive reporter gene than ,3-galactosidase, the levels that we obtained in all five colonies were up to five times higher than published luciferase expression levels in transgenic mice (33) (34) (35) (36) (37) (38) . Moreover, we showed that significant expression of the human 15-lipoxygenase can be directed to the vascular wall and the airway epithelium.
It is not certain whether species differences alone explain the differences between the two studies. We used the 5.9-kb 5'-flanking region of the murine promoter sequence that may have an endothelial specific element between -1.4 and -5.9 kb as discussed. We also include in our construct the first exon and 0.8 kb of the first intron. The human construct had only 4.4 kb of the 5'-flanking human endothelin-J promoter region sequence and no elements from the first exon or intron.
The murine preproendothelial targeting system achieved not only significant luciferase expression but expression of a biologically relevant gene product. Because 15-lipoxygenase is a lipid peroxidating enzyme capable of oxidating low density lipoproteins in vitro, it will be of interest to observe whether foam cells appear more readily in these transgenic mice. This will require cholesterol feeding after crossbreeding of the described heterozygotes to achieve appropriate genetic background. These studies can-now be pursued.
Because the murine PPET-J promoter sequence can direct expression of genes to the vascular wall in transgenic mice, a number of experiments addressing in vivo physiology and pathophysiology will be possible. Overexpression of select proteins will permit in vivo evaluation of biological sequelae that have been suggested from in vitro data. Moreover, expression of peptide inhibitors, soluble receptors, anti-sense RNA or other molecules that may not be bioavailable will allow the elucidation of in vivo vascular biology that would otherwise be difficult to assess. Furthermore, the ability to knock-out function in a restricted fashion may offer advantages over systemic approaches which effect a variety of systems and sometimes lead to lethal phenotypes. Finally, as gene therapy becomes more feasible, it is clear that one of its limitations is the inability to direct expression to the desired cells. Both the endothelial cells and airway epithelial cells are important targets for gene therapy in diseases such as atherosclerosis, restenosis, and cystic fibrosis. The current study suggests that preproendothelin 5'-flanking sequence may augment the ability to achieve expression in select somatic cells in gene therapy.
